An average of 516 construction workers would be at the site during the construction period; approximately 1,000 workers would be required during the peak construction period.

Demonstration (including performance testing and monitoring) would be conducted over a 3-year period. If the demonstration is successful, commercial operation would follow immediately. About 250 workers would be required during the demonstration, and 150 workers would be needed for long-term operations.

Proposed emissions from the facility would be small, especially for sulfur dioxide (SO<sub>2</sub>), because most of the sulfur would be removed from the synthesis gas prior to conveying the gas to the F–T liquefaction facilities and the combined cycle power plant. The use of anthracite culm would reduce waste disposal from operating mines and allow reclamation of land currently stock piled with culm.

### Availability of the Draft EIS

Copies of this Draft EIS have been distributed to Members of Congress, Federal, State, and local officials, and agencies, organizations and individuals who may be interested or affected. This Draft EIS will be available on the Internet at: <a href="http://www.eh.doe.gov/nepa/">http://www.eh.doe.gov/nepa/</a>. Additional copies can also be requested by telephone at (412) 386–4512, or (866) 576–8240. Copies of the Draft EIS are also available for public review at the locations listed below.

Frackville Free Public Library, 56 N. Lehigh Avenue, Frackville, PA 17931. Mahanoy City Public Library, 17–19 W. Mahanoy Avenue, Mahanoy City, PA 17948.

Pottsville Free Library, 215 West Market Street, Pottsville, PA 17901.

Issued in Washington, DC, on December 2, 2005.

#### Mark J. Matarrese,

NEPA Compliance Officer, Office of Fossil Energy.

[FR Doc. E5–7069 Filed 12–7–05; 8:45 am] BILLING CODE 6450–01–P

# FEDERAL ELECTION COMMISSION

### **Sunshine Act Notices**

**DATE AND TIME:** Tuesday, December 13, 2005 at 10 a.m.

**PLACE:** 999 E Street, NW., Washington, DC.

**STATUS:** This Meeting Will Be Closed to the Public.

**ITEMS TO BE DISCUSSED:** Compliance matters pursuant to 2 U.S.C. 437g.

Audits conducted pursuant to 2 U.S.C. 437g, 438(b), and Title 26, U.S.C. Internal personnel rules and procedures or matters affecting a particular employee.

DATE AND TIME: Thursday, December 15, 2005 at 10 a.m.

**PLACE:** 999 E. Street, NW., Washington, DC (Ninth Floor).

**STATUS:** This Meeting Will Be Open to the Public.

### ITEMS TO BE DISCUSSED:

Correction and Approval of Minutes Merit and Service Awards Election of Officers

Final Rules and Explanation and Justification for Electioneering Communications

Final Rules and Explanation and Justification for Extension of Administrative Fines Program Routine Administrative Matters

Person to Contact for Information: Mr. Robert Biersack, Press Officer, Telephone (202) 694–1220.

### Mary W. Dove,

Secretary of the Commission.
[FR Doc. 05–23838 Filed 12–6–05; 10:45 am]
BILLING CODE 6715–01–M

#### **FEDERAL RESERVE SYSTEM**

# Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than December 23, 2005.

A. Federal Reserve Bank of Cleveland (Cindy West, Manager) 1455 East Sixth Street, Cleveland, Ohio 44101-2566:

1. Jay L. Dunlap, Lincoln, Nebraska; acting as attorney and agent on behalf of Mark Dunlap; to vote shares of New Richmond Bancorporation and thereby indirectly acquire New Richmond National Bank, both of New Richmond, Ohio.

### B. Federal Reserve Bank of Atlanta (Andre Anderson, Vice President) 1000 Peachtree Street, NE., Atlanta, Georgia 30303:

1. Clara Brown,, Jasper, Tennessee; to acquire additional voting shares of General Bancshares, Inc., Jasper, Tennessee, and thereby indirectly acquire Citizens State Bank, Jasper, Tennessee.

Board of Governors of the Federal Reserve System, December 5, 2005.

#### Robert deV. Frierson,

Deputy Secretary of the Board. [FR Doc. E5–7061 Filed 12–7–05; 8:45 am] BILLING CODE 6210–01–8

### **FEDERAL RESERVE SYSTEM**

# Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center Web site at http://www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 3, 2005.

A. Federal Reserve Bank of Atlanta (Andre Anderson, Vice President) 1000 Peachtree Street, NE., Atlanta, Georgia 30303: 1. First Federal Bancorp, Columbia, Mississippi; to become a bank holding company upon the conversion of its wholly-owned thrift subsidiary, First Federal Bank for Savings, Columbia, Mississippi, to a state nonmember bank, to be known as First Southern Bank, Columbia, Mississippi.

Board of Governors of the Federal Reserve System, December 5, 2005.

#### Robert deV. Frierson,

Deputy Secretary of the Board. [FR Doc. E5-7060 Filed 12-7-05; 8:45 am] BILLING CODE 6210-01-S

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the Advisory Committee on Blood Safety and Availability

**AGENCY:** Department of Health and Human Services, Office of the Secretary. **ACTION:** Notice.

SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood Safety and Availability (ACBSA) will hold a meeting. The meeting will be open to the public.

**DATES:** The meeting will take place Thursday, January 5, 2006 and Friday, January 6, 2006 from 9 a.m. to 5 p.m. **ADDRESSES:** Marriott Crystal Gateway, 1700 Jeff Davis Highway, Arlington, VA 22202.

# FOR FURTHER INFORMATION CONTACT: Jerry

A. Holmberg, PhD, Executive Secretary, Advisory Committee on Blood Safety and Availability, Office of Public Health and Science, Department of Health and Human Services, 1101 Wootton Parkway, Room 250, Rockville, MD 20852, (240) 453–8809, FAX (240) 453–8456, e-mail

jholmberg@osophs.dhhs.gov.

SUPPLEMENTARY INFORMATION: The ACBSA will meet to review progress and solicit additional input regarding numerous recommendations made during the past year. Additionally, the Committee will discuss strategies for vigilant detection and management of emerging or re-emerging infectious and non-infectious events of transfusion since it is a necessary first step toward the goal of reducing the risk of transfusion-transmitted diseases as well as disease transmission through other vital products such as bone marrow,

progenitor cells, tissues, and organs. The Committee will also be asked to review current literature and hear subject matter experts on the H5NI avian flu virus and provide recommendations for preparations which should be considered for the nation's blood supply if a pandemic influenza or similar pandemic event occurs. Recommendations on the impact of a pandemic on the availability of blood, organs, and other tissue will be requested.

Public comment will be solicited at the meeting and will be limited to five minutes per speaker. Anyone planning to comment is encouraged to contact the Executive Secretary at his/her earliest convenience. Those who wish to have printed material distributed to Advisory Committee members should submit thirty (30) copies to the Executive Secretary prior to close of business January 3, 2006. Likewise, those who wish to utilize electronic data projection to the Committee must submit their materials to the Executive Secretary prior to close of business January 3, 2006.

# Jerry A. Holmberg,

Executive Secretary, Advisory Committee on Blood Safety and Availability.

[FR Doc. E5–7084 Filed 12–7–05; 8:45 am]

BILLING CODE 4150–41–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

[60 Day-06-0009]

# Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 404-639-4766 and send comments to Seleda Perryman, CDC Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail to omb@cdc.gov.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should be received within 60 days of this notice.

# **Proposed Project**

National Disease Surveillance Program—I. Case Reports—Revision— (NCID), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

Formal surveillance of 18 separate reportable diseases has been ongoing to meet the public demand and scientific interest in accurate, consistent, epidemiologic data. These ongoing disease reports include: Active Bacterial Core Surveillance (ABCs), Creutzfeldt-Jakob Disease (CJD), Cyclospora, Dengue, Hantavirus, Idiopathic CD4+Tlymphocytopenia, Kawasaki Syndrome, Legionellosis, Lyme disease, Malaria, Plague, Q Fever, Reye Syndrome, Tickborne Rickettsial Disease, Trichinosis, Tularemia, Typhoid Fever, and Viral Hepatitis. Tularemia is a new addition to this submission. Case report forms from state and territorial health departments enable CDC to collect demographic, clinical, and laboratory characteristics of cases of these diseases. This information is used to direct epidemiologic investigations, identify and monitor trends in reemerging infectious diseases or emerging modes of transmission, to search for possible causes or sources of the diseases, and develop guidelines for prevention and treatment. The data collected will also be used to recommend target areas most in need of vaccinations for selected diseases and to determine development of drug resistance.

Because of the distinct nature of each of the diseases, the number of cases reported annually is different for each. There is no cost to respondents other than their time.